Dermapharm Holding SE
DMP
ISIN DE000A2GS5D8 / Valor 40166352
Dermapharm Holding SE
UMushroom community rating:
About company
Dermapharm Holding SE is a pharmaceutical company that operates through its subsidiary HÜBNER Naturarzneimittel GmbH, also known as MEDOPHARM Arzneimittel GmbH & Co. KG. Founded in 1932 in Munich, the company specializes in natural preparations for pharmacies, particularly silica products. Dermapharm is a leading manufacturer of branded pharmaceuticals, medical devices, and food supplements, with a focus on steroids, dermatics, and painkillers. The company's integrated business model includes in-house development, production, and distribution of healthcare products in Germany, Europe, and the United States. With a strong emphasis on innovation and rapid growth, Dermapharm is dedicated to providing high-quality pharmaceuticals and healthcare products to its customers.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (10.10.2025):
Dermapharm Holding SE has released its preliminary financial results for the first half of 2025, showing a slight decline in consolidated revenue and adjusted EBITDA compared to the previous year. Despite these minor reductions, the branded pharmaceuticals segment remains strong, and Q2 2025 saw an increase in adjusted EBITDA compared to the prior-year quarter.
Consolidated Revenue
In H1 2025, Dermapharm reported consolidated revenue of EUR 574.5 million, a decrease of 0.7% compared to EUR 578.5 million in H1 2024.
Adjusted EBITDA
Adjusted EBITDA for H1 2025 was EUR 148.0 million, down 3.3% from EUR 153.0 million in the same period last year, resulting in an adjusted EBITDA margin of 25.8%.
Q2 2025 Performance
In Q2 2025, adjusted EBITDA grew by 3.7% compared to the prior-year quarter, indicating positive momentum in the second half of the year.
Branded Pharmaceuticals Segment
The branded pharmaceuticals segment achieved robust organic growth, particularly in the allergology therapeutic area and international markets, which offset declines in parallel imports and Arkopharma.
Other Healthcare Products
Revenue in the other healthcare products segment increased slightly, driven by Euromed’s B2B business, though earnings were affected by foreign exchange losses.
Parallel Import Business Restructuring
The parallel import business continued restructuring to focus on high-margin products, leading to a decline in revenue as the product portfolio shifts.
Full-Year Guidance
The Board of Management reaffirmed the full-year 2025 guidance, projecting consolidated revenue of EUR 1,160–1,200 million and adjusted EBITDA of EUR 322–332 million.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
2108 M
Market cap (USD)
40,084
Daily traded volume (Shares)
38.55 / 37.75
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
